SureTrader Advertisement Advertisement
Home > Boards > US OTC > Biotechs >

PharmaCyte Biotech Inc. (PMCB)

Add PMCB Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator mick, TraderpennyX, Peacefulwendy, The Promised Land, BioNewton, Peter
Search This Board:
Last Post: 11/26/2015 8:06:06 PM - Followers: 571 - Board type: Free - Posts Today: 4

Welcome to PharmaCyte BioTech

$PMCB Enjoy Corporate Video





$PMCB Enjoy Discovery Channel Video






$PMCB Enjoy Another Great Video YouTube TGen Leads the Way in Early Detection of Cancer. Dr. Von Hoff will lead $PMCB into FDA Fast Track Approval







FDA Grants Orphan Drug Designation to Nuvilex for Pancreatic Cancer Treatment

Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious:
Data from Two Clinical Trials in Pancreatic Cancer

ThaiTECT ???????? 14 - Drug Development Part I : International Experiences

Nuvilex/Austrianova declared the winner of the 2014 Best Innovation Award

Encapsulation of Insulin Producing Cells for Diabetes Treatment Using 
Alginate and Cellulose Sulphate as Bioencapsulation Polymers

NUVILEX (NVLX)- The Next Great Biotech Story (VIDEO)


PharmaCyte Company Address
   PharmaCyte BioTech, Inc.
   Meadows Corporate Park I
   12510 Prosperity Dr., Suite #310
   Silver Spring, MD 20904-1643
   Phone:  (877) 958-7616 , (917) 595-2850
   Fax: (917) 595-2851

Market Value:
$76,201,902 a/o Mar 11, 2015

Shares Outstanding:
699,292.029 a/o Dec 15, 2014

Authorized Shares:
1,490,000,000 a/o Aug 26, 2014

529,206,849 a/o Aug 26, 2014

Short Selling Data

Short Interest: 363,107 (1.685) a/o Feb 13, 2015

For more updated information please visit:

Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations

Jamien Jones 
Blueprint Life Science Group 
Telephone: 415.375.3340 Ext. 103 


All News Releases:

All Information about Nuvilex:

What is Cell-in-a-Box®?

The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients. 
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost. 
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool. 
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans. 

PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech's treatment for pancreatic cancer involves low doses of the well-known anticancer prodrug ifosfamide, together with encapsulated live cells, which convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This "targeted chemotherapy" has proven remarkably effective in past clinical trials. In addition, PharmaCyte Biotech is working towards improving the quality of life for patients with advanced pancreatic cancer and on treatments for other types of solid cancerous tumors.


Austria Nova Demonstration Video


SMMG Radio Interview with COO Dr. Crabtree ~ 2013

Shareholder Update with CEO & COO via SMMG Interview ~ July 2014

The proprietary technology can be used for a variety of purposes.

In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients.

In biotechnology, the Cell-in-a-Box™ technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost.

The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool

Management Team:


Kenneth L. Waggoner, Chief Executive Officer and President:

Further highlights of Mr. Waggoner’s career include leadership and legal positions with several start-up companies during the last several years as well as working with Fortune 500 companies most of his professional career.  During his tenure with Chevron, Mr. Waggoner served as the Vice President and General Counsel of its Global Downstream operations where he was responsible for the overall management of legal services to the North American, Latin American, Europe and Asian Products Companies.  At Chevron he led a successful restructuring of the company’s international Legal Department following Chevron’s acquisition of Texaco.Kenneth L. Waggoner has almost four decades of experience in management, business, operations and law.  Mr. Waggoner started his career as an attorney in private practice. Notably he was a senior partner with Brobeck, Phleger and Harrison, named one of the top two law firms worldwide that provide services to biotechnology clients including Chiron, Amgen, Biogen Idec, Sangamo, Ligand, DepoTech and many others.  He was the Managing Partner of Brobeck’s Los Angeles office.  Mr. Waggoner was also a member of the Executive Committee for almost ten years and on the Policy Committee for numerous years managing Brobeck’s worldwide operations with annual revenues in excess of $750,000,000.  While at Brobeck, Mr. Waggoner was the Co-Chairman of Brobeck’s world-wide Environmental Law Group.

Mr. Waggoner received his Juris Doctorate. with honors in 1973 from Loyola University School of Law in Los Angeles.


Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director:

Dr. Crabtree is the Company’s Chief Operating Officer.  Since 1985, Dr. Crabtree has been involved with various biopharmaceutical companies where he has alternatively supervised and coordinated the development of multiple drug candidates, prepared clinical protocols, investigator brochures, monographs, research and review articles and served as project manager for development of major oncologic agents.  He is a Member of the American Society of Clinical Oncology and also is a past member of research grant review committees for the National Institute of Health and the American Cancer Society.  Dr. Crabtree established and directed, from inception, a department that monitored and coordinated the development of oncologic and immunologic drugs from initial discovery through regulatory approval in a major pharmaceutical company and served as project manager for the development of the anticancer agent, Taxol®.

Dr. Crabtree received his Ph.D. in Biochemistry from the University of Alberta, Edmonton, Alberta, Canada and has published over 80 articles in peer-reviewed journals.  He is a National Cancer Institute of Canada Research Fellow.  In addition, he served as Department Head of Molecular Pharmacology for the Nucleic Acid Research Institute, and prior to that as Associate Professor of Medicine with the Roger Williams Cancer Center at Brown University.  Dr. Crabtree has also served as Director of Project Planning and Management (Oncology/Immunology) at Bristol-Myers Squibb and as Vice-President of Research and Development at ETEX Corporation.  Most recently, Dr. Crabtree served as Interim CEO of PhytoCeutica, Inc., where he assisted in preparation and review of FDA documents, clinical study protocols, investment acquisitions and contracts and business plans.

Walter H. Gunzburg – Chief Scientific Officer:

Prof. Walter H. Gunzburg is the co-founder, Chairman of the Board and Chief Technical Officer of Austrianova. As well as being a full Professor of Virology at the University of Vienna since 1996, he has had many years of experience in the biotech industry. He was a scientific advisor to the international vaccine company, Bavarian Nordic, from 1994-2001 and was involved in their IPO. He has also been an scientific advisor to the German biotech companies, Paktis and Liponova, as well as the U.S. biotech company, Tocagen Inc., all of which developed/are developing advanced medicinal treatments for cancer. He was also the Director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development from 2003-2011. Currently, he is a board member of ViruSure, a virus and prion testing company located in Vienna that he cofounded.

Prof. Gunzburg has been actively involved in European ethics and regulatory affairs in the fields of cell and gene therapy as well as xenotransplantation for many years. He was a member of the German Medical Association's Central Commission for Somatic Gene Therapy. He has also interacted with a number of regulatory agencies including the US FDA, EMA, TGA, HSA and Thai-FDA and was on the review panel for the Paul Ehrlich Institute, Langen, Germany. Prof. Gunzburg continues to be an active researcher and has published more than 130 peer-reviewed publications in international scientific and medical journals such as NatureThe Lancet,Proceedings of the National Academy of Sciences USA and Cancer Research as well as co-authoring the first German language textbook on gene therapy. He is also a member of the editorial board of a number of international cell and gene therapy journals including Trends in Molecular Medicine, and continues to be an active reviewer for many top tier journals as well as grant funding agencies.

Dr. Matthias Lohr as Chairman of Scientific Advisory Board:

Matthias Löhr was appointed professor of gastroenterology & hepatology at Karolinska Institutet in 2007, incoming from the Univ. Heidelberg/dkfz. From the times of his MD thesis through PhD and lateron, he concentrated on several aspects of the pancreas, both in clinical medicine, translational and basic sciences. He is heading the Pancreas Research Team at Gastrocentrum and leading the KICancer Diagnose-related network for HPB tumors. For hte European Gastroenterologists (UEG), he is sitting in several committees at the EU in Brussels. He is also leading the Pancreas 2000 program, an educational program for future pancreatologists in Europe.

Thomas Liquard - Chairman of the Audit Committe

Mr. Liquard is a seasoned pharmaceutical industry executive whose past experiences include serving as Chief Executive of Alchemia Limited and as Senior Director, Portfolio Development Leader, Emerging Markets for the Established Products portfolio for Pfizer in New York.


Dr. Eva Maria (Lilli) Brandtner – Director of Diabetes Program Development


Following receipt of her Doctorate in Natural Sciences in the areas of Biochemical Microbiology and Molecular Genetics in 2001, Dr. Brandtner served as a Postdoctoral Scientist and Senior Postdoctoral Fellow at Austrianova Biomanufacturing AG in Austria where she was involved in the development of retroviral vectors for gene therapy.  In 2007, Dr. Brandtner moved to Singapore and became Project Manager for work on the cell-based therapy of liver cancer at the same company.  Shortly thereafter, Dr. Brandtner was promoted to Senior Scientist at Austrianova Pte Ltd (Austrianova) where she oversaw the development of numerous projects concerned with live cell Bioencapsulation.  This was followed in 2010 by her promotion to Chief Scientist at Austrianova, responsible for all encapsulation projects in medicine and biology.  Most importantly, while at Austrianova, Dr. Brandtner was intimately involved in all of the preclinical work done there that included the use of live cell encapsulation in developing a treatment for insulin-dependent diabetes.  Due to family commitments, in 2012 Dr. Brandtner left Singapore to return to Austria where she is currently employed as Head of the Bioencapsulation Unit at the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT).

Dr. Brandtner is co-inventor on two granted patents and is named on several additional patents that are in preparation.  She has co-authored numerous research reports that have been published in reputable scientific journals and has presented research results at national and international scientific conferences and meetings.  Dr. Brandtner is a member of the European Association for the Study of Diabetes (EASD), the Austrian Diabetes Association (ÖDG) and the European Society for Gene and Cell Therapy (ESGCT).

Dr. Manuel Hidalgo, Scientific Advisory Board:

Manual Hidalgo is the Vice Director of Translational Research, Clinical Research Program Director and Head of Gastrointestinal Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO) and Director at the Centro Integral Oncologico Clara Campal (CIOCC). In addition he is a professor of Oncology at the University CEU San Pablo. Dr. Hidalgo was born in Antequera, Malaga, in 1968. He received his MD from the Universidad de Navarra, Pamplona, in 1992 and his PhD from the Universidad Autonoma de Madrid in 1997. Manuel specialized in Medical Oncology at the Hospital Universitario 12 de Octubre, Madrid, obtaining his license in 1996. He completed his training in drug development at the University of Texas Health Science Center, San Antonio (USA), where he briefly joined as Faculty. He then moved to Johns Hopkins University in 2001 as Co-Director of the Drug Development and GI Programs. He joined the CNIO in 2009 to lead the GI Cancer Clinical Research Unit. Manuel is a founding member of the Pancreatic Cancer Research Team (PCRT) - a clinical trials group focusing on novel therapeutics for pancreatic cancer. He has participated in the clinical development of more than 30 novel anticancer agents and led the early clinical trials with erlotinib and temsirolimus - two recently approved drugs. Manuel´s work has contributed to the incorporation of molecular endpoints in early clinical trials. His group pioneered the utilization of personalized xenograft models for drug screening, biomarker development and personalized cancer treatment. He has published more than 180 papers in peer-reviewed journals and his work has been funded by the NCI, AACR, and ASCO. Manuel received an AACR Clinical Research Fellowship and an ASCO Career Development Award for his work on the development of EGFR inhibitors. His most recent efforts focus on novel therapeutics for pancreatic cancer. - See more at:



Stock Chart
Company Info
Recent News
Filings and Disclosure
Short Sales
Insider Disclosure
Research Reports
Historical Prices
Interactive Chart
Basic Chart
Basic Tech. Analysis
Press Releases
Company Profile
Key Statistics
Major Holders
Insider Transactions
Insider Roster
Income Statement
Balance Sheet
Cash Flow
Market Watch
OTC Short Report


•The Board Monitor and The Board Assistants herewith, are not licensed brokers and
assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.

•We do NOT recommend that anyone buy or sell any securities posted herewith.
Any trade entered into risks the possibility of losing the funds invested.
•There are no guarantees when buying or selling any security.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
PMCB News: PharmaCyte Biotech Provides Link to Orphan Drug Designation for Its Pancreatic Cancer Treatment 11/24/2015 09:25:00 AM
PMCB News: PharmaCyte Biotech Announces Appointment of International Diabetes Expert to Scientific Advisory Board 11/19/2015 10:41:11 AM
PMCB News: PharmaCyte Biotech Appoints International Diabetes Expert to Its Scientific Advisory Board 11/19/2015 09:25:00 AM
PMCB News: PharmaCyte Biotech Obtains Orphan Drug Designation in Europe for Its Pancreatic Cancer Treatment 11/17/2015 09:22:24 AM
PMCB News: PharmaCyte Biotech Scientific Advisory Board Member Named Clinical Director of Prestigious Boston Cancer Center 11/10/2015 10:18:08 AM
#43686  Sticky Note PMCB News! PharmaCyte Biotech Provides Link to Orphan TraderpennyX 11/24/15 09:37:01 AM
#43664  Sticky Note $PMCB PharmaCyte Biotech Obtains Orphan Drug Designation Peter 11/23/15 02:11:18 AM
#43225  Sticky Note I think the thing that continues to get BioNewton 11/09/15 07:23:18 PM
#42788  Sticky Note $PMCB ~ PharmaCyte Biotech, Inc. DD All Ab Peter 10/31/15 12:56:42 AM
#18112  Sticky Note EVERYONE please keep your posts on-topic. The topic IH Geek [Dave] 03/14/14 12:28:20 PM
#43760   I believe the ema ascities is going to Brian903 11/26/15 08:06:06 PM
#43759   Yes, I distinctly remember reading that article and rudygerner 11/26/15 07:25:43 PM
#43758   $PMCB 'Cell-in-a-Box' May Help Treat Malignant Fluid Accumulation Malignant Peter 11/26/15 11:30:58 AM
#43757   Something to chew on pun intended efood125 11/26/15 10:50:31 AM
#43756   Thank you my Friend ;-) Go $PMCB Peter 11/25/15 10:43:33 PM
#43755   'Peter', Happy Thanksgiving to you and all here pennyvestor 11/25/15 09:29:48 PM
#43754   $PMCB TD2 helping PMCB for Clinical Trials and Peter 11/25/15 01:10:12 PM
#43753   cGMP and a buyout (or two) will happen. BioNewton 11/25/15 12:46:00 PM
#43752   Keep tabs on has been that way efood125 11/25/15 12:02:12 PM
#43751   I SEE NEWS THIS MORNING, PMCB mick 11/25/15 10:22:23 AM
#43750   EARNINGS, MULTIPLES HIGHER AVERAGES. mick 11/25/15 10:21:26 AM
#43749   i see some greens this morning, animal mick 11/25/15 10:19:50 AM
#43748 mick 11/25/15 10:17:59 AM
#43747   WHAT AH TABLE, i am hungry now. mick 11/25/15 10:17:23 AM
#43746   Maybe he means it is 36 days till Brian903 11/25/15 10:16:36 AM
#43745   Happy Thanksgiving to you Mick and Everyone Here Peter 11/25/15 10:13:24 AM
#43744   its make as much sense as you saying thenewmixer 11/25/15 10:12:08 AM
#43743   This makes zero sense. It's 36 days BioNewton 11/25/15 10:05:55 AM
#43741   PMCB countdown continues 36 days until next Delay thenewmixer 11/25/15 09:44:43 AM
#43740   Strong buys coming in and then a crazy Brian903 11/25/15 09:44:30 AM
#43739   That stock shares the same manipulation as PMCB rudygerner 11/25/15 09:28:18 AM
#43738 The Promised Land 11/25/15 07:29:15 AM
#43737 PharmaCyte B The Promised Land 11/25/15 04:08:07 AM
#43736   Hotelier A great deal has gone on since your The Promised Land 11/25/15 03:45:12 AM
#43735   This sentence proves there is no knowledge of BioNewton 11/24/15 10:49:05 PM
#43734   1. What is EMA? European Medical Association? Peter 11/24/15 10:29:24 PM
#43733   Since you mentioned Sanofi, they are funding Mannkind Peter 11/24/15 08:53:01 PM
#43732   Sorry. I know too much to think BioNewton 11/24/15 08:40:55 PM
#43730   What is EMA? European Medical Association? And GMP Shakey88 11/24/15 07:39:56 PM
#43729   See, Pharmacyte/Nuvilex PAYS TD2. They don't do this Hotelier51 11/24/15 07:17:47 PM
#43728   Dr. Von Hoff and Dr. Lohr are hardly BioNewton 11/24/15 07:13:09 PM
#43727 rudygerner 11/24/15 07:02:03 PM
#43726   Here's the thing...Kalobios is a legit company. They Hotelier51 11/24/15 06:52:10 PM
#43725   Exactly take as an example kalobios Pharmaceuticals mddoctor 11/24/15 06:36:48 PM
#43724   PharmaCyte Biotech Inc. OTC: PMCB mick 11/24/15 05:15:53 PM
#43723   Here are examples from social media that should BioNewton 11/24/15 04:56:10 PM
#43722   $PMCB nice closed today Go $PMCB Peter 11/24/15 04:30:27 PM
#43721   Here is who knows about PMCB. Shareholders, BioNewton 11/24/15 04:26:15 PM
#43720   You keep assuming idealistic scenarios which is where A_realist 11/24/15 04:15:14 PM
#43719   As explained over 300 times. This is BioNewton 11/24/15 04:10:25 PM
#43718   This information is all laid out on the BioNewton 11/24/15 03:59:40 PM
#43717   more PMCB smoke and mirrors thenewmixer 11/24/15 03:09:19 PM
#43715   Get real...EMA ODD is meaningless? Rofl....all the efood125 11/24/15 02:27:32 PM
#43712   lucky 8s are here ;-) GO $PMCB Shrimp2Whales 11/24/15 01:34:43 PM
#43711   I feel the most for PMCBs shareholders........ oh thenewmixer 11/24/15 01:14:38 PM
#43710   $PMCB Enjoy Corporate Video That Treat Sic Peter 11/24/15 12:42:37 PM
#43708   No, the EMA did that as part of BioNewton 11/24/15 12:37:20 PM
#43706   OMG Those Sham Artists. All they did was Hotelier51 11/24/15 12:18:56 PM
#43705   Looking good, what another great piece of news today! The Promised Land 11/24/15 10:33:08 AM
#43704   Exactly Bull. I cannot believe it was BioNewton 11/24/15 10:25:33 AM